Prothena Q3 2026 net loss narrows to $16.5M
Nine-month revenue was primarily from a $50.0 million Novo milestone, and Prothena repurchased 2,745,380 shares through September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Prothena Corporation plc reported third-quarter 2026 revenue of $0.6 million and net loss of $16.5 million, compared with $2.4 million and $36.5 million a year earlier. For the first nine months, revenue was $52.7 million versus $9.7 million, primarily from a $50.0 million Novo milestone payment; net loss was $2.4 million versus $222.5 million. At September 30, 2026, cash, cash equivalents and restricted cash totaled $272.2 million, and Prothena had no debt.
Net cash used in operating and investing activities was $12.0 million in the third quarter and $8.9 million in the first nine months. Prothena repurchased 2,745,380 ordinary shares for $26.6 million during the first nine months, excluding commissions and expenses, under its up to $100.0 million program, which expires December 31, 2026. The company continues to expect full-year 2026 net cash use of $18 million to $23 million and approximately $259 million in year-end cash, cash equivalents and restricted cash at the midpoint. Partner-led Phase 3 trials of prasinezumab and coramitug have primary completion expected in 2029.
2 points · 1 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointNine-month net loss: $2.4 million, versus $222.5 million in 2025.
- Moderate pointNine-month revenue: $52.7 million, versus $9.7 million in 2025.
Negative
- Minor pointThird-quarter revenue: $0.6 million, versus $2.4 million in 2025.
Filing Explained
Prothena’s 2026 net cash-use and year-end cash guidance excludes potential additional share-repurchase spending, so any such spending before the program’s
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Third-quarter total revenue: $0.6 million
First nine months total revenue: $52.7 million
Third-quarter net loss: $16.5 million
+5 more
8 metrics
Third-quarter total revenue
$0.6 million
Third quarter 2026; $2.4 million in third quarter 2025
First nine months total revenue
$52.7 million
First nine months 2026; $9.7 million in the same period of 2025
Third-quarter net loss
$16.5 million
Third quarter 2026; $36.5 million in third quarter 2025
First nine months net loss
$2.4 million
First nine months 2026; $222.5 million in the same period of 2025
Cash, cash equivalents and restricted cash
$272.2 million
As of September 30, 2026
2026 expected net cash used in operating and investing activities
$18 million to $23 million
Full-year 2026 guidance
Expected year-end cash, cash equivalents and restricted cash
Approximately $259 million
Full-year 2026 guidance, at the midpoint
Share repurchases
2,745,380 ordinary shares for $26.6 million
First nine months of 2026; excluding commissions and expenses
Key Terms
hsCRP, ATTR-CM, NT-proBNP, Fast Track designation
4 terms
hsCRP medical
"inflammatory biomarker hsCRP"
ATTR-CM medical
"ATTR amyloidosis with cardiomyopathy (ATTR-CM)"
NT-proBNP medical
"previously reported reduction in NT-proBNP"
A blood test marker released when the heart is under strain; higher NT‑proBNP levels indicate the heart is working harder or may be failing, similar to a dashboard warning light that signals engine stress. Investors watch NT‑proBNP because changes in the marker can drive clinical trial results, treatment approvals, hospital use, and insurance decisions for heart drugs and devices, all of which affect revenue, adoption and valuation in healthcare companies.
Fast Track designation regulatory
"Coramitug granted Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Earnings Snapshot
Third-quarter total revenue: $0.6 million · Guidance included
Third quarter and first nine months of 2026
Third-quarter total revenue
$0.6 million
Compared with $2.4 million in the third quarter of 2025
First nine months total revenue
$52.7 million
Compared with $9.7 million in the first nine months of 2025
Third-quarter net loss
$16.5 million
Compared with $36.5 million in the third quarter of 2025
First nine months net loss
$2.4 million
Compared with $222.5 million in the first nine months of 2025
Guidance
The company continues to expect full-year 2026 net cash used in operating and investing activities of $18 million to $23 million and approximately $259 million in year-end cash, cash equivalents and restricted cash at the midpoint.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were PRTA's third-quarter 2026 revenue and net loss?
Prothena reported third-quarter revenue of $0.6 million and net loss of $16.5 million. In the first nine months of 2026, revenue was $52.7 million and net loss was $2.4 million; nine-month revenue was primarily from a $50.0 million Novo milestone payment.
What is PRTA's 2026 cash-use guidance?
Prothena continues to expect full-year 2026 net cash used in operating and investing activities of $18 million to $23 million. It expects to end the year with approximately $259 million in cash, cash equivalents and restricted cash at the midpoint.
When are PRTA partner-led Phase 3 trials expected to complete?
Roche's PARAISO trial of prasinezumab and Novo's CLEOPATTRA trial of coramitug each have primary completion expected in 2029. PARAISO is being conducted in approximately 900 participants and CLEOPATTRA in approximately 1,280 participants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2026
_______________________________________________________
(Exact name of registrant as specified in its charter)
_______________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices, including Zip Code) | ||||||||||||||||||||
Registrant’s telephone number, including area code: 011-353 -1 -236-2500
___________________________________________________
(Former Name or Former Address, if Changed Since Last Report.)
___________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. | ||||
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically incorporate by reference the information furnished pursuant to Item 2.02 (including Exhibit 99.1) of this Current Report.
On November 5, 2026, Prothena Corporation plc issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of that press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits | ||||
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press Release dated November 5, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | November 5, 2026 | PROTHENA CORPORATION PLC | ||||||||||||
| By: | /s/ Tran B. Nguyen | |||||||||||||
| Name: | Tran B. Nguyen | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
Exhibit 99.1
PRESS RELEASE
Prothena Reports Third Quarter 2026 Financial Results and Business Highlights
•Net cash used in operating and investing activities was $12.0 million in the third quarter and net cash used in operating and investing activities was $8.9 million for the first nine months of 2026; quarter-end cash and restricted cash position was $272.2 million
•Novo recently presented post hoc analyses at the Heart Failure Society of America (HFSA) Annual Scientific Meeting from the coramitug Phase 2 trial which demonstrated a decrease of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) in patients treated with coramitug as compared to an increase in patients on placebo, further supporting the potential of coramitug as a treatment for ATTR-CM
•Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months
DUBLIN, Ireland, November 5, 2026 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2026 and provided business highlights.
“During the quarter, Roche and Novo highlighted prasinezumab at Roche’s Pharma Day and coramitug at Novo’s Capital Markets Day, underscoring the potential of these Prothena-originated programs to address significant unmet needs in Parkinson’s disease and ATTR amyloidosis with cardiomyopathy, respectively. Novo also recently presented a post hoc analysis of the Phase 2 trial at the HFSA Annual Scientific Meeting showing that the inflammatory biomarker hsCRP decreased from baseline in patients treated with coramitug, while increasing in those receiving placebo. These findings complement the previously reported reduction in NT-proBNP and favorable functional and echocardiographic findings, further supporting coramitug’s potential as an amyloid-depleting treatment for ATTR-CM. Both programs are in Phase 3 clinical trials, PARAISO (prasinezumab) and CLEOPATTRA (coramitug), with primary completions expected in 2029,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. “Bristol Myers Squibb continues to conduct the Phase 2 TargetTau-1 trial evaluating moponetug in patients with early Alzheimer’s disease, with data readout expected in the first half of 2027. Through our partnered programs, we have generated $650 million in upfront, milestone and equity payments and may potentially receive over $2.25 billion in additional milestone payments, plus potential royalties. Additionally, we are progressing our wholly-owned preclinical programs, including PRX012-TfR and TDP-43 CYTOPE. And finally, we continue to evaluate our proprietary CYTOPE® technology with industry partners through multiple research collaborations over the next 12 to 24 months.”
Business Highlights and Upcoming Milestones
Clinical Development Portfolio
Prasinezumab, a potential first-in-class antibody for the treatment of Parkinson’s disease that is designed to target a key epitope within the C-terminus of alpha-synuclein and is the focus of a worldwide collaboration with Roche.
•Roche is conducting the Phase 3 PARAISO clinical trial in approximately 900 participants for a minimum of 104 weeks with early-stage Parkinson's disease on stable symptomatic monotherapy with levodopa; primary completion expected in 2029 (NCT07174310)
•Roche has stated that prasinezumab has peak sales potential greater than $3.5 billion (unadjusted) and could be the first disease-modifying treatment for Parkinson’s disease—a condition that affects 10 million people worldwide
Coramitug (formerly PRX004), a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) designed to deplete the pathogenic, non-native forms of the transthyretin (TTR) protein, is being developed by Novo as part of its up to $1.2 billion acquisition of Prothena’s ATTR amyloidosis business and pipeline.
•Novo is conducting the Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)
•Novo recently presented post hoc analyses of its Phase 2 coramitug trial at the HFSA Annual Scientific Meeting. At week 52, the pooled coramitug dose groups (10 and 60 mg/kg) reported an ~8% decrease of the inflammatory biomarker hsCRP, compared with an ~33% increase with placebo (treatment ratio versus placebo: 0.66; nominal p=0.0269)
•Open-label study ongoing to evaluate the biodistribution of 89Zr-coramitug and investigate the effects of coramitug on depleting TTR amyloid deposits in myocardial tissues using PET/CT imaging in participants with ATTR-CM; primary completion expected in 2027 (NCT07448623)
•Coramitug granted Fast Track designation from the U.S. FDA for the treatment of ATTR-CM
Moponetug (formerly PRX005), a potential best-in-class antibody for the treatment of Alzheimer’s disease that specifically targets a key epitope within the microtubule binding region (MTBR) of tau, a protein implicated in the causal pathophysiology of Alzheimer’s disease.
•Bristol Myers Squibb is conducting the Phase 2 TargetTau-1 clinical trial in approximately 310 patients with early Alzheimer’s disease; expected data readout in 1H 2027 (NCT06268886)
•Bristol Myers Squibb is conducting a Phase 1, open-label, multi-part study to evaluate pharmacokinetics, absolute bioavailability, safety, tolerability, and immunogenicity of single-dose moponetug following intravenous and subcutaneous administrations in healthy adults and multiple doses of moponetug in participants with early Alzheimer's disease; primary completion expected mid-2027 (NCT07780383)
•Bristol Myers Squibb conducted a Phase 1 open-label single-dose clinical trial to assess a subcutaneous administration (NCT06955741)
•Moponetug granted Fast Track designation by U.S. FDA as a treatment for Alzheimer’s disease
Preclinical Development Portfolio
TDP-43 CYTOPE®, a wholly-owned proprietary preclinical program for precision intracellular targeting of TDP-43 pathology, a defining pathogenic feature of ALS and other TDP-43 proteinopathies. TDP-43 CYTOPE preclinical data demonstrates the potential of Prothena’s CYTOPE technology to target intracellular disease pathways.
•Prothena presented a poster at Neuroscience 2025 (Society for Neuroscience), as well as encore presentations at the International Symposium of ALS/MND 2025 and the 2026 European Network
to Cure ALS (ENCALS) demonstrating the activity of TDP-43 CYTOPE in multiple preclinical models
PRX012-TfR, a wholly-owned preclinical program combining PRX012, our single-injection, once-monthly antibody delivered subcutaneously with proprietary transferrin receptor technology to potentially improve its product profile for the treatment of Alzheimer’s disease.
•Preclinical studies ongoing to support potential efficacy of PRX012-TfR
Third Quarter of 2026 Financial Results
For the third quarter and first nine months of 2026, Prothena reported net loss of $16.5 million and $2.4 million, respectively, as compared to a net loss of $36.5 million and $222.5 million for the third quarter and first nine months of 2025, respectively. Basic and dilutive net loss per share was $0.32 and $0.05, for the third quarter and first nine months of 2026, respectively, as compared to a basic and dilutive net loss per share of $0.68 and $4.13, respectively, for the third quarter and first nine months of 2025.
Prothena reported total revenue of $0.6 million and $52.7 million for the third quarter and first nine months of 2026, respectively, as compared to total revenue of $2.4 million and $9.7 million for the third quarter and first nine months of 2025, respectively. Total revenue for the first nine months of 2026 was primarily from $50.0 million in milestone payment from Novo related to ongoing Phase 3 clinical trial for coramitug and collaboration revenue from Bristol Myers Squibb related to the partial performance of our PRX019 Phase 1 clinical trial obligation. Total revenue for the third quarter and first nine months of 2025, was primarily from collaboration revenue from Bristol Myers Squibb related to the partial performance of our PRX019 Phase 1 clinical trial obligation.
Research and development (R&D) expenses totaled $8.4 million and $29.9 million for the third quarter and first nine months of 2026, respectively, as compared to $28.9 million and $120.3 million for the third quarter and first nine months of 2025, respectively. The decrease in R&D expenses for the third quarter and first nine months of 2026 compared to the same periods in the prior year was primarily due to lower clinical trial expenses, lower personnel expenses and lower consulting expenses. R&D expenses included non-cash share-based compensation expense of $1.8 million and $5.4 million for the third quarter and first nine months of 2026, respectively, as compared to $2.5 million and $12.0 million for the third quarter and first nine months of 2025, respectively.
General and administrative (G&A) expenses totaled $10.6 million and $34.2 million for the third quarter and first nine months of 2026, respectively as compared to $13.2 million and $46.7 million for the third quarter and first nine months of 2025, respectively. The decrease in G&A expenses for the third quarter and first nine months of 2026 compared to the same periods in the prior year was primarily due to lower personnel expenses and consulting expenses. G&A expenses included non-cash share-based compensation expense of $4.6 million and $14.0 million for the third quarter and first nine months of 2026, respectively, as compared to $4.7 million and $16.5 million for the third quarter and first nine months of 2025, respectively.
Prothena recorded restructuring expenses of $0.4 million for the third quarter and an aggregate restructuring credit of $1.4 million for the first nine months of 2026, respectively, as compared to $0.5 million for the third quarter and $33.1 million for the first nine months of 2025, respectively. Restructuring expenses included non-cash share-based compensation expense of $1.7 million for the first nine months of 2026, as compared to $2.1 million for the first nine months of 2025.
Total non-cash share-based compensation expense was $6.4 million and $21.2 million for the third quarter and first nine months of 2026, respectively, as compared to $7.2 million and $30.6 million for the third quarter and first nine months of 2025, respectively.
As of September 30, 2026, Prothena had $272.2 million in cash, cash equivalents and restricted cash, and no debt.
As of October 29, 2026, Prothena had approximately 51.3 million ordinary shares outstanding.
2026 Financial Guidance
The Company continues to expect its full year 2026 net cash used in operating and investing activities to be $18 to $23 million and to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash. The estimated full year 2026 net cash used in operating and investing activities is primarily driven by an estimated net loss of $25 to $30 million, which includes an estimated $26 million of non-cash share-based compensation expense. This financial guidance does not include any potential additional cash utilized as part of a share repurchase program.
3Q 2026 Share Repurchase Program
Prothena repurchased 501,492 ordinary shares in the third quarter of 2026. Together with the 788,990 and 1,454,898 ordinary shares repurchased in the first and second quarter of 2026, respectively, Prothena repurchased an aggregate of 2,745,380 ordinary shares during the first nine months of 2026 with $26.6 million, excluding commissions and expenses, under its up to $100.0 million share repurchase program, which expires on December 31, 2026.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and Amyotrophic lateral sclerosis (ALS). Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of our pipeline and completion of our ongoing clinical trials; the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of our CYTOPE® technology and expected milestones in 2027, and beyond; the treatment potential, designs, proposed mechanisms of action, and potential administration of prasinezumab, coramitug, moponetug, TDP-43 CYTOPE, and PRX012-TfR; plans for ongoing and future clinical trials of prasinezumab, coramitug, and moponetug; the expected timing of reporting data from preclinical studies and clinical trials; projections regarding peak sales and patient population for prasinezumab; amounts we may receive under our collaborations with Roche, Novo, and Bristol Myers
Squibb; our anticipated net cash burn from operating and investing activities for 2026 and expected cash balance at the end of 2026; our estimated net loss and non-cash share-based compensation expense for 2026; and the potential to return capital to shareholders via a share repurchase program or other permissible means. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
PROTHENA CORPORATION PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited - amounts in thousands except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Collaboration revenue | $ | 620 | $ | 2,415 | $ | 2,664 | $ | 9,613 | ||||||||||||||||||
| Revenue from license and intellectual property | — | — | 50,050 | 50 | ||||||||||||||||||||||
| Total revenue | 620 | 2,415 | 52,714 | 9,663 | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Research and development | 8,427 | 28,938 | 29,852 | 120,266 | ||||||||||||||||||||||
| General and administrative | 10,594 | 13,238 | 34,159 | 46,746 | ||||||||||||||||||||||
| Restructuring costs | 420 | 479 | (1,410) | 33,088 | ||||||||||||||||||||||
| Total operating expenses | 19,441 | 42,655 | 62,601 | 200,100 | ||||||||||||||||||||||
| Loss from operations | (18,821) | (40,240) | (9,887) | (190,437) | ||||||||||||||||||||||
| Other income, net | 2,314 | 3,328 | 7,521 | 11,187 | ||||||||||||||||||||||
| Loss before income taxes | (16,507) | (36,912) | (2,366) | (179,250) | ||||||||||||||||||||||
| Provision for (benefit from) income taxes | 2 | (371) | 5 | 43,253 | ||||||||||||||||||||||
| Net loss | $ | (16,509) | $ | (36,541) | $ | (2,371) | $ | (222,503) | ||||||||||||||||||
| Basic and diluted net loss per ordinary share | $ | (0.32) | $ | (0.68) | $ | (0.05) | $ | (4.13) | ||||||||||||||||||
| Shares used to compute basic and diluted net loss per share | 51,437 | 53,830 | 52,422 | 53,828 | ||||||||||||||||||||||
PROTHENA CORPORATION PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited - amounts in thousands)
| September 30, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Assets | |||||||||||
| Cash and cash equivalents | $ | 271,368 | $ | 307,531 | |||||||
| Prepaid expenses and other current assets | 2,494 | 7,662 | |||||||||
| Total current assets | 273,862 | 315,193 | |||||||||
| Property and equipment, net | 2,299 | 2,144 | |||||||||
| Operating lease right-of-use assets | 6,017 | 8,125 | |||||||||
| Restricted cash, non-current | 860 | 860 | |||||||||
| Other non-current assets | 482 | 482 | |||||||||
| Total non-current assets | 9,658 | 11,611 | |||||||||
| Total assets | $ | 283,520 | $ | 326,804 | |||||||
| Liabilities and Shareholders’ Equity | |||||||||||
| Accrued research and development | $ | 489 | $ | 4,329 | |||||||
Deferred revenue, current | — | 2,664 | |||||||||
Restructuring liability | 587 | 13,303 | |||||||||
| Lease liability, current | 3,007 | 2,886 | |||||||||
| Other current liabilities | 7,351 | 17,661 | |||||||||
| Total current liabilities | 11,434 | 40,843 | |||||||||
| Lease liability, non-current | 3,249 | 5,487 | |||||||||
Total non-current liabilities | 3,249 | 5,487 | |||||||||
| Total liabilities | 14,683 | 46,330 | |||||||||
| Total shareholders’ equity | 268,837 | 280,474 | |||||||||
| Total liabilities and shareholders’ equity | $ | 283,520 | $ | 326,804 | |||||||
Contacts:
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com